CatalystFDA/Bio

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

Moderna's 9% surge on Phase 3 melanoma data and presidential symposium slot drives biotech catalyst.

What changed

Moderna's 9% surge on Phase 3 melanoma data and presidential symposium slot drives biotech catalyst.

Why it matters

Moderna's 9% surge on Phase 3 melanoma data and presidential symposium slot drives biotech catalyst. — impact context not separately stored; see What changed.

Sources

eodhd